BioLineRx (BLRX) Misses Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to BioLineRx (BLRX) Misses Q1 EPS by 2c

Roth Affirms BioLineRx (BLRX( at 'Buy'; Balance Sheet Strong as BL-8040 Momentum Builds

May 17, 2016 2:15 PM EDT

Roth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q1 results reported earlier. BLRX reported Q1 EPS of ($0.10), which was $0.02 worse than the analyst estimate of ($0.08).

Analyst Joseph Pantginis commented, BL-8040 continues to be the lead value driver with initial positive data in r/rAML, an ongoing Phase II in consolidation AML and positive stem cell... More